NCT01265030 - A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 22, 2021

Study Completion Date

December 22, 2021

Conditions

Desmoid Tumor

Interventions

DRUG

Sirolimus

"* Loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligrams)~* Starting 24 hours after the initial loading dose, patients will receive a dose of 4 milligrams/meter2 daily; Per Os (PO), by mouth days 2 through 28 (Max dose 4 milligram/day)"

Trial Locations (8)

32611

University of Florida College of Medicine, Gainesville

53226

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Minneapolis

64108

Children's Mercy Hospital, Kansas City

90095

UCLA Medical Center, Los Angeles

92123

Rady Children's Hospital, San Diego

98101

Seattle Children's Hospital, Seattle

04102

Maine Medical Center, Portland